Navigation Links
Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Date:2/11/2009

ALISO VIEJO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call on Tuesday, February 24, 2009 at 11:00 a.m. EST (8:00 a.m. PST) to discuss results for the 2008 fourth quarter and year.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 83660030. International callers should dial (973) 200-3961, confirmation code 83660030. A replay will be available approximately two hours following the conclusion of the conference call to Tuesday, March 3, 2009, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 83660030.

The company also will webcast the call live over the Internet, which will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie W. Little, Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
5. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
6. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
7. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
8. Pharmaceuticals sold in Sweden cause serious environmental harm in India
9. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
10. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a trusted advisor to the U.S. ... industry white paper, entitled Barriers to Adoption of the ERA and EFT Transactions ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), ... magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist ... incorporate magnesium, a critical property for bone health and development. , “We’re excited ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, ... making a distinct rather than generic impression in the job market if one is ... stack of resumes knows that the first impression they give off is not a ...
(Date:9/19/2017)... IL (PRWEB) , ... September 19, 2017 , ... ... significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... Emergency Nursing (BCEN). The value of certification study, conducted by the Human Resources ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... 2017 Sapheneia and Scannerside received FDA 510(k) ... is a third-party Vendor neutral CT product that makes ... compliance with current MITA standards. ... solution is specifically designed to provide CT operators, prior ... doses over a predefined threshold. Scannerside Dose Check is ...
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
Breaking Medicine Technology: